Introduction
The introduction of beta-receptor blocking agents in the treatment of angina pectoris has been an important advance in this difficult therapeutic field. Pronethalol was the first drug of this type to be used successfully in treating angina (Dornhorst and Robinson, 1962) , but was soon replaced by propranolol, which was more potent and was also free of the undesirable side-effects of pronethalol (Black et al., 1964) . Propranolol itself, however, may lead to adverse effects on myocardial function (Chamberlain, 1966; Stephen, 1966) and also on the bronchial tree (McNeill, 1964) . The development of practolol (4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide; I.C.I. 50172; Eraldin) was therefore of considerable interest, since this drug appears to be a cardioselective betablocking agent with some intrinsic sympathomimetic activity (Barrett et al., 1968) which might have no deleterious effects on myocardial function. A preliminary study of the use of practolol in normal and anginal subjects gave encouraging results (Areskog and Adolfsson, 1969) , but the route of administration of the drug was mainly intravenous. It was decided, therefore, to carry out a controlled double-blind evaluation of oral practolol in the treatment of angina, basing the assessment primarily on objective criteria provided by exercise tolerance tests, and at the same time a comparison was made in the same patients between practolol and propranolol, which has already established itself widely in the treatment of angina (Gillam and Prichard, 1965; Hamer and Sowton, 1966; Wolfson et al., 1966 ).
Patients and Methods
Sixteen patients with typical attacks of angina pectoris entered the study. There were 11 men and five women aged 33 to 64 years. None was suffering from or had previously developed left or right ventricular failure. Myocardial infarction had occurred in three, but at least one year had elapsed since the episode, and in all the patients studied the angina *ConsultanX Physician, St. Helen Hospital, Barnsley.
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had settled down to a relatively stable pattern. Glyceryl trinitrate was taken freely for the anginal attacks, the weekly consumption ranging from 1 to 139 tablets. All patients showed S-T depression in the electrocardiogram on exercise, ensuring that an objective index of myocardial ischaemia was present for evaluation of drug action. The preparations studied were practolol, propranolol 80 mg. q.d.s., and a placebo, a double-blind technique being employed. The dose of propranolol used for comparison was decided on the basis of studies indicating the adequacy of this dose in treating angina (Hamer et al., 1964; Keelan, 1965 (Sandler, 1961) . In addition to conventional electrocardiography recording chest lead V15 before and after exercise, the patient was monitored continuously during exercise by radiocardiography, which is more sensitive in revealing ischaemic change and also safer by ensuring that ischaemic change can be detected immediately, especially if unaccompanied by angina, allowing the exercise to be terminated immediately (Sandler, 1967) . Depression of the S-T segment of plane or sagging contour lasting at least 0.08 second in either the radiocardiogram or V5 was accepted as indicating myocardial ischaemia (Lloyd-Thomas, 1961; Master and Rosenfeld, 1961; Bellet et al., 1962) ; junctional depression was accepted as significant only when the QX/QT ratio exceeded 50°', (Master and Rosenfeld, 1961) . The indices of assessment which were recorded during the exercise test were the number of circuits accomplished by the patient and the exercise time before angina, or ischaemic change, or both, developed in the electrocardiogram; the duration of angina; the degree and duration of S-T depression either in the radiocardiogram or in lead V5; and the heart rate before and during exercise. In addition, the resting blood pressure was measured in the lying and standing positions before each exercise test was begun, to determine whether any of the preparations taken during the previous month had exerted a hypotensive effect. The nature and the purpose of the investigation were made clear to all the patients, and all gave their consent to it.
In addition to exercise electrocardiography each patient had an assessment of respiratory function by means of the Vitalograph, the indices recorded being the forced expiratory volume at one second (F.E.V.1) and the forced mid-expiratory flow (F.M.F.) (middle 5000 of the forced vital capacity) which give a satisfactory indication of the development of bronchospasm (Leuallen and Fowler, 1955) . Other screening investigations during the study included haemoglobin, white cell count, platelet count, blood urea, and liver function tests (serum bilirubir, alkaline phosphatase, zinc sulphate turbidity, and alanine aminotransferase).
Results
In view of thic well-known placebo response in antianginal trials (Greiner et al., 1950 ) the results obtained with practolol aind pi-opranolol were assessed by comparison with the placebo period and not with the control period. radiocardiogram during exercise was significantly reduced by practolol compared with the placebo, but propranolol had no significant effect. Neither practolol nor propranolol significantly influenced the degree of S-T depression after exercise in V5. The duration of S-T depression in either the radiocardiogram or in lead V5 was not significantly affected by either practolol or propranolol; the apparent discrepancies between the mean change figures and the figures obtained by subtracting the group means from each other is due to the differing numbers of patients contributing to the mean change result and the mean result. Whereas the mean for each group was calculated by averaging all patients showing S-T depression in that group, the mean change between two different groups-for example, placebo and practolol-was calculated by averaging the individual differences only in patients showing S-T depression in both groups, so that patients exhibiting S-T depression in one only treatment group were excluded from the estimation of mean change results.
Both practolol and propranolol produced a significant reduction in heart rate before and immediately after exercise, and, in addition, practolol, but not propranolol, significantly reduced the mean change between the pre-exercise and post-exercise heart rate (Table IV) . Both drugs significantly reduced-the systolic pressure, whether lying or standing (Table V) . Practolol also produced a significant fall in the standing diastolic pressure while propranolol significantly -Dosage and Side-effects
The dose of practolol used in the trial ranged from 200 to 600 mg. b.d., the dose for individual patients being determined in the "open" part of the trial at the beginning of the study. The side-effects of practolol included dizziness in five patients.(though none showed an unduly low blood pressure), depression in. three, and nausea and vomiting in three. Gastrointestinal upsets also occurred in two patients treated with propranolol, and another patient had dizziness on propranolol. While having placebo treatment, four patients also developed side-effects, including dizziness, blurred vision, and diarrhoea. Practolol had no effect on the routine screening tests, such as haemoglobin, white cell count, platelet count, blood urea, and liver function tests.
Discussion
The value of sympathetic beta-receptor blocking agents in the treatment of angina has already been well -established (Gillam and Prichard, 1965; Birkett and -Chamberlain, 1966; Grant et al., 1966; Sandler et al., 1968) , and the present study confirms the efficacy of the new beta-blocking drug, practolol, in treating this condition. Though practolol did not significantly affect the subjective criteria, including the number of attacks recorded by the patient or the glyceryl trinitrate consumption, it did significantly improve the more objective indices of myocardial ischaemia, such as the amount of exercise possible and, more important, the degree of ischaemic S-T depression in the radiocardiogram during exercise; in this respect it was superior to propranolol in a dose of 80 mg. q.d.s., which did not significantly alter the amount of S-T depression induced by exercise. The betablocking action of both drugs was confirmed by the significant reduction in heart rate produced by them, both in the resting patient and following exercise. The favourable effect of practolol on coronary insufficiency is unlikely to be due solely to its negative chronotropic action and may be associated primarily with reduction of myocardial contractility (Areskog and Adolfsson, 1969) .
Two of the main disadvantages encountered with propranolol treatment have been the deleterious effect on myocardial function due to its negative inotropic action (Chamberlain, 1966; Shanks, 1966; Stephen, 1966) and bronchospasm due to beta-receptor blockade in the bronchial tree (McNeill, 1964 (Barrett et al., 1968) , and, unlike propranolol, practolol was also round to have some intrinsic sympathomimetic action and no local anaesthetic (quinidine-like) action . In view of these considerations practolol might be expected to exert a less adverse effect on myocardial function than propranolol. A negative inotropic effect, however, has been found by Gibson and Sowton (1968) and Sowton et al. (1968) when using a large intravenous dose of 25 mg., though it was not evident with a 5-mg. dose of practolol. Possibly the significant fall in systolic pressure (lying and standing) produced by practolol in the present study may represent a negative inotropic effect, though the accompanying fall in heart rate induced by practolol may also be an important factor in this respect. There is as yet no convincing evidence that practolol can be given with impunity to patients with cardiac failure, and it would be advisable to continue to administer the drug cautiously when myocardial dysfunction is present. The bronchospastic effect of propranolol has been confirmed in the present study, while practolol was found to exert no significant effect on small airway resistance in our 15 patients. This confirms other studies showing that doses of practolol which were capable of blocking cardiac betareceptors had no significant effects on the beta-receptors of vascular and bronchial smooth muscle (Barrett et al., 1968; McDonald and McNeill, 1968) . This represents an important advantage of practolol over propranolol, since it means that practolol can be used freely in a large section of the population with combined angina and asthmatic bronchitis, where propranolol may adversely affect the respiratory function.
The blood pressure response to practolol in the present study is worthy of comment. It has been claimed that practolol has no significant effect on vascular smooth muscle, but there was a significant fall in the standing diastolic pressure following treatment with the drug. This suggests that practolol in the dose range used in the present study does in fact have some effect on the peripheral arterioles, and this may well have been an important factor in the patient who developed severe hypotension while having practolol and had to be withdrawn from the trial. Hence a close watch should be kept on the blood pressure whenever an anginal patient is treated with practolol, just as similar close observation is required with propranolol treatment.
We Introduction Pharmacological blockade of the sympathetic nervous impulses to the heart is now an accepted method of treatment for angina (British Medical 7ournal, 1969 quency of angina attacks and the consumption of glyceryl trinitrate (Gillam and Prichard, 1965; Keelan, 1965; Grant et al., 1966; Gianelly et al., 1967) . All beta-adrenergic agents, however, may increase airways resistance, especially when there is a tendency to asthma (MacDonald et al., 1967) . As angina and obstructive airways diseases, not uncommonly exist in the same patient, the respiratory problems may be aggravated and prevent the administration of the optimum dose of beta-blocking drug. Practolol is cardioselective and causes less increase in airways resistance than propranolol (MacDonald and McNeill, 1968) . A preparation of this kind could offer certain practical advantages over propranolol. Therefore a controlled trial was conducted in order to assess the efficacy of practolol in angina pectoris.
Patients and Methods
The first aim was to establish the dose of practolol at which symptomatic relief was obtained, but an arbitrary upper limit
